Yingxi Xu
Overview
Explore the profile of Yingxi Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1330
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu S, Liu L, Zhao Y, Ye B, He J, Li W, et al.
MedComm (2020)
. 2025 Feb;
6(2):e70090.
PMID: 39949981
Diet rich in chicken protein has gained a widespread popularity for its profound effect on weight loss and glycemic control; however, its long-term effect on cardiovascular health and the underlying...
2.
Li Y, Dong X, Xing H, Liu W, Gu R, Qiu S, et al.
Free Radic Biol Med
. 2025 Jan;
228:379-391.
PMID: 39814107
U2AF1 is a core component of spliceosome and controls cell-fate specific alternative splicing. U2AF1 mutations have been frequently identified in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients, and...
3.
Ma H, Yan Z, Gu R, Xu Y, Qiu S, Xing H, et al.
Cancer Immunol Immunother
. 2024 Nov;
74(1):20.
PMID: 39535595
Background: Immunotherapy, such as chimeric antigen receptor T (CAR-T) cells targeting CD33 or CD123, has been well developed over the past decade for the treatment of acute myeloid leukemia (AML)....
4.
Yu Y, Jiang X, Yu T, Chen F, Huang R, Xun Z, et al.
Biomaterials
. 2024 Oct;
314:122863.
PMID: 39366185
Sarcopenia is a progressive skeletal muscle disorder characterized by the accelerated loss of muscle mass and function, with no promising pharmacotherapies. Understanding the imbalance of myoprotein homeostasis within myotubes, which...
5.
Yan Z, Gu R, Ma H, Chen N, Zhang T, Xu Y, et al.
Cell Oncol (Dordr)
. 2024 Jul;
47(5):1879-1895.
PMID: 39008193
Background: Immunotherapies, including chimeric antigen receptor (CAR) T cells and bispecific antibodies (BsAbs), encounter several challenges in the management of acute myeloid leukemia (AML), including limited persistence of these treatments,...
6.
Xu Y, Liu X, Ahmad M, Ao Q, Yu Y, Shao D, et al.
Mater Today Bio
. 2024 Jul;
27:101125.
PMID: 38979129
Extracellular matrices (ECMs) play a key role in nerve repair and are recognized as the natural source of biomaterials. In parallel to extensively studied tissue-derived ECMs (ts-ECMs), cell-derived ECMs (cd-ECMs)...
7.
Li H, Cao Z, Liu Y, Xue Z, Li Y, Xing H, et al.
Mol Oncol
. 2024 Jun;
18(10):2554-2568.
PMID: 38922758
Persistence of quiescent leukemia stem cells (LSCs) after treatment most likely contributes to chemotherapy resistance and poor prognosis of leukemia patients. Identification of this quiescent cell population would facilitate eradicating...
8.
Zhou S, Liu L, Ye B, Xu Y, You Y, Zhu S, et al.
EBioMedicine
. 2024 May;
104:105150.
PMID: 38728837
Background: Non-high-density lipoprotein cholesterol (non-HDL-c) was a strong risk factor for incident cardiovascular diseases and proved to be a better target of lipid-lowering therapies. Recently, gut microbiota has been implicated...
9.
Shen J, Lyu S, Xu Y, Zhang S, Li L, Li J, et al.
Cell Stem Cell
. 2024 May;
31(7):1003-1019.e9.
PMID: 38723634
Generation of chimeric antigen receptor macrophages (CAR-Ms) from human pluripotent stem cells (hPSCs) offers new prospects for cancer immunotherapy but is currently challenged by low differentiation efficiency and limited function....
10.
Liu X, Sun H, Zheng L, Zhang J, Su H, Li B, et al.
Obes Rev
. 2024 Apr;
25(7):e13748.
PMID: 38590187
Adipose tissue is the first and primary target organ of obesity and the main source of circulating miRNAs in patients with obesity. This systematic review aimed to analyze and summarize...